# Questions, answered to the evidence

> FAQ — Research Peptide Fundamentals Research Peptides | Boston Peptide — Answers to common questions about Research Peptide Fundamentals research peptides, including GHK-Cu, semaglutide, tesamorelin, and BPC-157.

**REFERENCE DESK / COMMON QUESTIONS**

Direct answers on identity, mechanisms, claims, approvals, and the limits of current peptide research.

## What does a GHK-Cu peptide do?

GHK-Cu binds copper and participates in signaling associated with extracellular-matrix production, tissue remodeling, antioxidant activity, and repair. Human evidence is concentrated in topical skin and hair-adjacent work, while many broader claims come from cells, animals, or reviews [1][3][6]. It is more accurate to describe what each model found than to assign the peptide one universal effect.

## What is GHK-Cu and how does it work?

GHK is a three-amino-acid sequence; GHK-Cu is its copper complex. The copper-bound form can present copper to biological systems and influence fibroblast activity, matrix turnover, and several repair-related signaling programs. Cultured human fibroblasts increased collagen synthesis without a change in cell number [7]. Delivery through intact skin remains a formulation challenge [1].

## Is GHK-Cu peptide really anti-aging?

“Anti-aging” is too broad for the evidence. Reviews and small topical studies report changes in procollagen, collagen production, and some skin measures [1][4]. Those findings support continued skin research. They do not prove whole-body age reversal, and broad gene-expression results should not be read as clinical rejuvenation [2].

## What is the difference between GHK and GHK-Cu?

GHK is the free tripeptide glycyl-histidyl-lysine. GHK-Cu is that peptide coordinated to a copper ion. Copper binding is part of the proposed biological activity, so studies of free GHK and the intact complex are not automatically interchangeable.

## What is semaglutide used for?

Semaglutide is an approved prescription GLP-1 receptor agonist with specific formulations and indications. Large trials have studied weight management, cardiovascular outcomes, and kidney outcomes in defined populations [9][10][11]. The approved label for a given product sets its use; a literature summary does not provide individual treatment guidance.

## How does semaglutide work for weight loss?

Semaglutide activates GLP-1 receptors in metabolic and appetite pathways. It increases satiety, reduces food intake, slows gastric emptying, and supports glucose-dependent insulin signaling. A randomized trial found a greater mean body-weight reduction than placebo in adults with overweight or obesity without diabetes [11].

## What is tesamorelin?

Tesamorelin is a synthetic GHRH analogue. It prompts the pituitary to release endogenous growth hormone, which raises IGF-1 and influences fat metabolism. Its US approval is limited to reducing excess abdominal fat in adults with HIV-associated lipodystrophy [14].

## Will tesamorelin help with ordinary belly fat?

The strongest trials concern visceral fat in adults with HIV-associated lipodystrophy [13][15][17]. Those findings cannot be assumed to apply to general abdominal weight loss, healthy aging, or physique goals. This site does not turn a population-specific result into a personal recommendation.

## Is BPC-157 a growth hormone?

No. BPC-157 is a synthetic fifteen-amino-acid peptide, not growth hormone. Some laboratory work discusses growth-related or repair signaling, but its clearest mechanistic literature centers on pathways such as VEGFR2-linked angiogenesis [21].

## What does BPC-157 do in the body?

That question is not settled in humans. In animal and cell models, BPC-157 has been linked to angiogenesis, gastric protection, and repair pathways [21][22]. A recent review found human evidence extremely limited and large rigorous trials absent [19]. Model findings should not be restated as proven human effects.

## Does BPC-157 work immediately?

Published evidence does not establish a reliable human onset of benefit. Online timing claims are anecdotal, not clinical evidence. The available human pilot literature is too small to define effectiveness, onset, or a dependable safety profile [18][19].

## Does BPC-157 damage the liver?

The available human evidence is far too thin to answer that question confidently. A tiny pilot observed no measured hepatic biomarker change in two healthy adults [18], but that cannot rule out uncommon, delayed, or context-specific injury. Reviews continue to classify the compound as investigational [19].

---

Boston Peptide is an independent Massachusetts-framed literature desk for peptide mechanisms, trials, and regulatory context, not a clinic, seller, or source of medical advice.